Immune Responses to Two Dose Varivax +/- MMR-II

Stopped early · Phase 1/Phase 2

Conditions studied: Measles, Mumps, Rubella, Varicella

In brief

This study will test the safety and how well the body's immune system responds to a live, but weakened varicella (chickenpox) vaccine, known as Varivax, given with and without ProQuad, another measles, mumps, rubella, and varicella virus vaccine (MMR-II). One hundred five healthy children will be enrolled in the study when they are 12 months old. All subjects will be vaccinated at 12 months of age and some subjects will receive a second vaccination at 18 months of age. All subjects will participate for 1 year. This study is a single-site, two-year trial with post-licensure vaccines.

Key facts

Study ID

NCT00258726

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

105

Starts

2005-10-01

Expected to finish

2007-07-01

Last updated by the study team

2010-08-27

Who can join

Age: 1 and older, up to 1. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy infants 12 months (+ 4 weeks) of age.
• Free of obvious health problems as established by medical history and clinical examination before entering into the study. This includes all chronic health problems and immunodeficiencies.
• Parent/legal guardian has provided signed, written informed consent.
• Parent/legal guardian expected to be available for entire study.
• Parent/legal guardian can be reached by telephone.

You may not qualify if…

• Former premature infants (<36 weeks).
• Birth weight < 2500 grams.
• Significant underlying chronic illness.
• Immunodeficiency disease or use of immunosuppressive therapy by the participant.
• Any other condition that in the clinical judgment of the investigator might interfere with vaccine evaluation.
• Allergy to any components of the vaccine, including anaphylaxis or anaphylaxoid reaction to neomycin or eggs for MMR-II, and/or hypersensitivity to gelatin and anaphylaxis or anaphylaxoid reaction to neomycin for Varivax.
• Plans for participation in another clinical trial with an investigational drug or vaccine for the duration of this study.
• Blood products within 3 months prior to initial enrollment.
• Previous receipt of MMR and Varivax or ProQuad.

Where it is running

• Stanford University — Stanford, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.